Sorry, made an error in my calculation. Here's an adjusted...

Sorry, made an error in my calculation. Here's an adjusted version of my post. With only 60 participants in the BTX 1801 phase 2a trial, it is possible the number of people with MRSA were too low to glean statistically valid information. E.g. a 2013 article noted that 0.8% of staph colonised individuals have MRSA. So, based on that estimate, that is 0.48 people out of 60 = 0.24 people per group (active and placebo).

This would clearly be too low a number to provide statistically significant results. I think a key to the current BTX 1801 study result is that the primary endpoints were met. The statement by Professor Geoffrey Coombs is very positive for this phase 2a study: Professor Geoffrey Coombs, Murdoch University’s Chair of Public Health, commented: “BTX 1801's observed upfront eradication rates and sustained eradication effect, following treatment period, is very encouraging. Data from the BTX 1801 study represents a significant milestone and enhances the potential of better infection prevention measures in surgical settings to combat the growing global development of antibiotic resistance.”